Retatrutide:
A Research
Overview
Retatrutide is a synthetic polypeptide reported to act as an agonist at three receptors — GLP-1, GIP and glucagon. It sits within the field of incretin and metabolic receptor research. It is an investigational compound with no marketing authorisation, supplied strictly for research use only.
What retatrutide is
Retatrutide is a synthetic polypeptide described in the literature as a single molecule with reported agonist activity at three distinct receptors: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. This triple-receptor profile is what distinguishes it within its class.
It is supplied as a lyophilised powder for laboratory use. Like other peptides in this area it requires reconstitution with a solvent such as bacteriostatic water before use in any solution-phase research.
Background
Retatrutide belongs to the lineage of incretin research that produced first single-receptor and then dual-receptor agonists. The triple-agonist concept represents a further step in that line of investigation: a single molecule engaging three metabolic receptors simultaneously, studied as a way to understand combined receptor signalling.
It is an investigational compound. It has not received marketing authorisation from the MHRA, the FDA or any other regulator, and it has not been established as safe or effective for any use in humans. It is supplied strictly as a reference material for laboratory research.
Areas of research interest
Research involving retatrutide sits within metabolic receptor pharmacology — the study of how receptor signalling contributes to processes such as glucose handling and energy balance in model systems. Specific themes in the literature include:
- Incretin receptor signalling — how the GLP-1 and GIP receptors behave when engaged.
- Multi-receptor agonism — the effect of engaging three receptors with one molecule, versus one or two.
- Metabolic pathway models — laboratory systems used to study energy metabolism.
These are descriptions of research activity. Nothing here is a claim about what retatrutide does in a person, and no such claim would be lawful for an unlicensed compound.
Research context
Retatrutide is frequently discussed alongside earlier single- and dual-agonist peptides in the same literature, and comparative studies of the three approaches are a recurring theme. See our comparison of retatrutide, semaglutide and tirzepatide. The product listing sets out the specification and the batch certificate of analysis.
Frequently Asked Questions
Retatrutide is a synthetic polypeptide reported to act as an agonist at three receptors — the GLP-1, GIP and glucagon receptors. This triple-receptor profile distinguishes it within its class. It is supplied as a lyophilised powder for laboratory research use only.
No. Retatrutide is an investigational compound. It holds no marketing authorisation from the MHRA, FDA or any other regulator and has not been established as safe or effective for any use in humans. It is supplied strictly as a reference material for laboratory research.
It refers to a single molecule reported to activate three different receptors — in retatrutide's case the GLP-1, GIP and glucagon receptors — rather than one or two. It is a description of receptor-binding activity studied in the laboratory.